Background
Methods
Approvals
Subjects and procedures
Non-TXA | TXA | p value | |
---|---|---|---|
Age (years) | 69 ± 1 | 65 ± 1 | 0.092 |
Weight (kg) | 91 ± 5 | 90 ± 6 | 0.930 |
No. of patients | 11 | 12 | |
Gender | M = 4 | M = 2 | |
F = 7 | F = 10 | ||
Osteoarthritis | 11 | 12 | |
TXA administration: | |||
IV Infusion (mg/kg) | NA | 13.5 ± 0.6 | |
IA Injection (mg/kg) | NA | 15.5 ± 0.7 | |
Preoperative: | |||
Hemoglobin (HgB) g/L | 136 ± 4 | 137 ± 4 | 0.980 |
Anesthetic: | |||
General only | 0 | 1 | |
General + Spinal | 11 | 11 | |
Perioperative: | |||
Tourniquet time (Min) | 62 ± 11 | 27 ± 6 | 0.023* |
Surgical time (Min) | 107 ± 6 | 104 ± 4 | 0.566 |
Postoperative: | |||
HgB g/L day 1 | 121 ± 3§ | 122 ± 3§ | 0.787 |
HgB g/L day 2 | 111 ± 2§ | 121 ± 5§ | 0.093 |
TXA administration
Clinical assessments
Blood sampling
Rotational thromboelastometry
Cytokine analysis
Statistics
Results
Perioperative characteristics
Non-TXA | TXA | p value | |
---|---|---|---|
Preoperative: | |||
ROM | |||
Flexion (°) | 115 ± 5 | 121 ± 5 | 0.411 |
Extension (°) | 5 ± 1 | 2 ± 1 | 0.046* |
KOOS Total | 46 ± 6 | 41 ± 4 | 0.470 |
KOOS Pain | 10 ± 2 | 8 ± 1 | 0.417 |
KOOS Function | 32 ± 4 | 29 ± 3 | 0.457 |
KOOS Movement | 4 ± 0.7 | 4 ± 0.4 | 1.000 |
OKS | 22 ± 3 | 29 ± 3 | 0.457 |
EQ5D 3L VAS | 64 ± 7 | 67 ± 4 | 0.760 |
Postoperative 6 weeks: | |||
ROM | |||
Flexion (°) | 104 ± 5 | 110 ± 4§ | 0.297 |
Extension (°) | 7 ± 1 | 4 ± 1 | 0.134 |
KOOS Total | 26 ± 4§ | 17 ± 3§ | 0.096 |
KOOS Pain | 5 ± 1§ | 4 ± 1§ | 0.304 |
KOOS Function | 18 ± 3§ | 11 ± 2§ | 0.098 |
KOOS Movement | 3 ± 0.5 | 2 ± 0.3§ | 0.063 |
OKS | 27 ± 2 | 32 ± 2 | 0.097 |
EQ5D 3L VAS | 67 ± 7 | 75 ± 4 | 0.339 |
FJS | 62 ± 4 | 52 ± 6 | 0.170 |
Inflammatory status before, during and following surgery
Coagulation parameters
EXTEM
Test | Group | Time | CT (s) | CFT (s) | Alpha Angle (°) | LI30 (%) | LI45 (%) | ML (%) |
---|---|---|---|---|---|---|---|---|
EXTEM | Non-TXA | Baseline | 59 ± 3 | 96 ± 2 | 72 ± 3 | 100 ± 0 | 98.1 ± 0.4 | 3.1 ± 1.0 |
Bone Cut | 53 ± 1 | 76 ± 7 | 76 ± 2* | 100 ± 0 | 97.4 ± 0.5 | 6.3 ± 0.8* | ||
Surgery End | 51 ± 3 | 75 ± 7 | 73 ± 3 | 100 ± 0 | 98.7 ± 0.3¥ | 3.9 ± 0.6¥ | ||
TXA | Baseline | 64 ± 4 | 70 ± 7 | 76 ± 1 | 98.8 ± 1.2 | 95.6 ± 1.9 | 7.9 ± 1.9 | |
Bone Cut | 59 ± 5 | 67 ± 6 | 78 ± 1 | 99.8 ± 0.3 | 97.3 ± 0.6 | 6.5 ± 1.0 | ||
Surgery End | 65 ± 3¶ | 89 ± 14 | 73 ± 2 | 100 ± 0 | 98.3 ± .4 | 4.4 ± 0.8 | ||
FIBTEM | Non-TXA | Baseline | 59 ± 6 | 884 ± 476 | 76 ± 1 | 99.1 ± 0.9 | 99.3 ± 0.7 | 1.4 ± 1.3 |
Bone Cut | 53 ± 3 | 797 ± 604 | 73 ± 2 | 100 ± 0 | 99.9 ± .10 | 0.5 ± 0.3 | ||
Surgery End | 49 ± 2 | 1483 ± 576 | 67 ± 7 | 99.9 ± 0.1 | 100 ± 0 | 0.4 ± 0.2 | ||
TXA | Baseline | 66 ± 5 | 1020 ± 480 | 74 ± 2 | 100 ± 0 | 99.5 ± 0.23 | 1.1 ± 0.4 | |
Bone Cut | 54 ± 4* | 403 ± 300 | 76 ± 1* | 98.8 ± 0.7 | 98.3 ± 1.1 | 2.8 ± 1.3 | ||
Surgery End | 68 ± 5¶ | 480 ± 301 | 70 ± 2 | 99.9 ± 0.1 | 99.8 ± 0.2 | 1.1 ± 0.4 | ||
INTEM | Non-TXA | Baseline | 204 ± 15 | 104 ± 16 | 71 ± 2 | 99.7 ± 0.3 | 97.7 ± 0.7 | 4.6 ± 1.0 |
Bone Cut | 164 ± 10* | 71 ± 8* | 76 ± 2* | 99.7 ± 0.2 | 96.6 ± 0.5 | 6.3 ± 0.6 | ||
Surgery End | 162 ± 13* | 69 ± 10* | 73 ± 2 | 100 ± 0 | 98.3 ± 0.4 | 4.1 ± 0.8 | ||
TXA | Baseline | 170 ± 11 | 69 ± 8¶ | 76 ± 2¶ | 99.7 ± 0.1 | 95.9 ± 0.5 | 6.8 ± 0.8 | |
Bone Cut | 149 ± 8* | 65 ± 4 | 77 ± 1 | 99.8 ± 0.1 | 97 ± 0.6* | 5.8 ± 0.7 | ||
Surgery End | 154 ± 12 | 101 ± 31 | 73 ± 4 | 100 ± 0* | 97.9 ± 0.4§ | 4.8 ± 0.7§ |
FIBTEM
INTEM
Discussion
-
Elevated baseline plasma levels of MCP-1 and TNF-α relative to healthy, aged-matched human values, indicating the presence of low-grade systemic inflammation prior to surgery.
-
After the first bone cut and surgery end, MCP-1, TNF-α, IL-1β and IL-6 (after surgery) were significantly increased in TXA compared to non-TXA patients, with differences further amplified at postoperative days 1 and 2. TXA appeared to exacerbate the surgical stress inflammatory response.
-
EXTEM CT was prolonged in TXA patients after the first bone cut and at surgery end, indicating a thrombin-slowing effect on clot initiation, despite little or no change in clot amplitude or fibrinogen levels.
-
In TXA patients there was a tendency for increased FIBTEM maximum lysis during surgery, a finding that is counter to TXA’s antifibrinolytic effect.
-
Maximum lysis in EXTEM and INTEM was < 5% and < 7%, respectively during surgery, indicating little or no hyperfibrinolysis, and supported by similar falls in hemoglobin levels (11–19%) on days 1 and 2 postoperative relative to baseline. These data question the need for TXA in this surgical setting.